It has been another busy week for many of Australia's top brokers. This has led to the release of a number of broker notes.
Three broker buy ratings that you might want to know more about are summarised below. Here's why brokers think these ASX shares are in the buy zone right now:
Image source: Getty Images
CSL Ltd (ASX: CSL)
According to a note out of Goldman Sachs, its analysts have initiated coverage on this biotechnology giant's shares with a buy rating and $325.40 price target. Goldman Sachs is feeling very positive about CSL's outlook and is forecasting double-digit immunoglobulin (IG) growth each year through to FY 2028. It expects this to be underpinned by low penetration and ~100 basis points year on year market share gains. Another positive is that Goldman highlights that its channel checks indicate that CSL's competitive advantages are intact, with the expansion in fractionation capacity set to enhance CSL's superior cost profile and supply reliability. This is expected to lead to margin expansion and strong earnings growth in the coming years. The CSL share price is trading at $276.86 on Friday.
NextDC Ltd (ASX: NXT)
A note out of Morgans reveals that its analysts have retained their add rating on this data centre operator's shares with a slightly trimmed price target of $20.00. Morgans has been updating its financial model ahead of earnings season. After factoring in its recent capital raising, the broker has trimmed its price target. However, it remains very positive on the company and its outlook. Morgans continues to believe that NextDC is well-placed to benefit from the structural growth in demand for data centres. The NextDC share price is fetching $15.58 at the time of writing.
ResMed Inc. (ASX: RMD)
Another note out of Goldman Sachs reveals that its analysts have initiated coverage on this sleep disorder treatment company's shares with a buy rating and $48.90. According to the note, the broker believes that ResMed is well-positioned to achieve the top end of is FY 2030 revenue financial target. This implies a compound annual growth rate of 8.9% between FY 2025 and FY 2030. It expects this to be underpinned by robust Continuous Airway Pressure Therapy (CPAP) patient growth, assisted by growing awareness on Obstructive Sleep Apnoea (OSA), market share gains, particularly in OSA masks, and operating margin expansion driven by product mix and solid cost management. The ResMed share price is trading at $38.24 on Friday morning.
